NYSE · AZN
Healthcare · Drug Manufacturers - General
$165.41
Down-$1.27 (-0.76%)
Updated Oct 19, 2026, 8:08 AM
SID Score
7.3/10
Composite research score
Smart Money
59/100
Neutral
Price performance · AZN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
AZN closed at $165.41 after 20 trading sessions, down 1.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $166.97 | $167.18 | $164.365 | $165.41 | 3.46M |
| Oct 15, 2026 | $167.69 | $169.81 | $166.49 | $166.68 | 4.4M |
| Oct 14, 2026 | $158.71 | $162.71 | $158.31 | $162.03 | 3.33M |
| Oct 13, 2026 | $160.76 | $160.83 | $154.00 | $155.82 | 3.11M |
| Oct 12, 2026 | $159.44 | $159.44 | $157.60 | $158.33 | 2.86M |
| Oct 9, 2026 | $159.45 | $160.065 | $158.53 | $159.20 | 2.12M |
| Oct 8, 2026 | $159.80 | $160.05 | $156.72 | $158.78 | 3.49M |
| Oct 7, 2026 | $159.12 | $161.29 | $158.53 | $160.12 | 2.46M |
| Oct 6, 2026 | $159.795 | $159.96 | $156.26 | $158.61 | 2.05M |
| Oct 5, 2026 | $156.76 | $157.20 | $154.81 | $156.53 | 2.26M |
| Oct 2, 2026 | $158.46 | $158.795 | $156.41 | $156.90 | 3.04M |
| Oct 1, 2026 | $160.77 | $161.325 | $157.54 | $157.70 | 3.38M |
| Sep 30, 2026 | $164.47 | $164.484 | $161.46 | $161.47 | 2.23M |
| Sep 29, 2026 | $165.09 | $166.465 | $163.24 | $164.21 | 3.37M |
| Sep 28, 2026 | $165.69 | $167.52 | $165.39 | $166.15 | 1.73M |
| Sep 25, 2026 | $166.16 | $166.81 | $164.60 | $166.58 | 2.07M |
| Sep 24, 2026 | $162.91 | $166.25 | $162.91 | $164.56 | 3.19M |
| Sep 23, 2026 | $166.58 | $167.59 | $163.33 | $163.33 | 2.36M |
| Sep 22, 2026 | $167.84 | $169.35 | $166.74 | $168.37 | 2.31M |
| Sep 21, 2026 | $168.45 | $169.00 | $167.11 | $168.10 | 2.94M |
The latest Smart Investors Daily articles mentioning AZN.
Company
Market Activity
Research & News
AZN research
Company profile and research snapshot.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
Generated Oct 18, 2026, 9:07 PM
AstraZeneca shares declined 0.76% today as the market digests mixed signals—including a valuation reassessment at 14.6x forward earnings alongside positive strategic developments. Despite the modest pullback, the company is advancing its innovation pipeline through major partnerships that could reshape its long-term growth trajectory.
Bottom line: AstraZeneca's slight decline appears more tactical than fundamental, with the 14.6x forward earnings valuation offering potential value for patient investors. The $1.5 billion AI partnership is a meaningful positive catalyst, though investors should monitor execution risks, patent cliff dynamics, and regulatory headwinds while the company navigates its innovation transition.
Yahoo · Oct 16, 2026
AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The underperformance is significant for investors to consider because AstraZeneca’s operating results have remained relatively strong, and that makes its valuation more interesting. Instead of asking whether the stock is simply cheap after falling, investors need to […]
Yahoo · Oct 16, 2026
This deal with insitro sees AstraZeneca double down on its intention to enter the growing MASH market.
Yahoo · Oct 15, 2026
Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.
Yahoo · Oct 15, 2026
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 2.3% and the S
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC shares currently trade at $165.41, reflecting a modest one-month decline of 0.44% but a strong one-year gain of 94.33%, per SID market data. The stock sits above its 50-day moving average of $162.13 but remains below its 200-day moving average of $170.64, suggesting near-term recovery within a broader consolidation phase. The 14-day relative strength index stands at 48.8, indicating neutral momentum with no overbought or oversold conditions present. AZN carries a notably low beta of 0.168, according to Massive/Polygon data, underscoring the stock's defensive characteristics relative to the broader market. Average daily trading volume registers at approximately 5.47 million shares. The company's market capitalization stands at roughly $279.9 billion, positioning AstraZeneca among the largest pharmaceutical companies globally. Three-month performance shows a slight positive return of 0.54%, reflecting relative price stability during the period.
AstraZeneca PLC trades at a price-to-earnings ratio of 33.06, representing a premium relative to the broader healthcare sector, according to SID market data. The company's PEG ratio stands at 4.53, suggesting the current earnings multiple substantially exceeds the firm's projected growth rate, per SEC filings. AZN's price-to-book ratio of 6.24 further reflects a significant premium to book value, consistent with investor expectations for the company's oncology and rare disease pipeline. The dividend yield sits at approximately 1.56%, providing modest income for shareholders relative to the elevated earnings multiple. With a market capitalization of approximately $279.9 billion, AstraZeneca commands one of the richest valuations in the large-cap pharmaceutical space. The combination of a high PE ratio and elevated PEG ratio indicates that the market is pricing in sustained long-term revenue and earnings growth driven by the company's expanding therapeutic portfolio and global commercial footprint.
AstraZeneca PLC registers an overall smart money score of 59 out of 100 with a neutral signal, according to SID market data. Institutional ownership strength scores a perfect 25 out of 25, reflecting robust conviction among large asset managers and pension funds. Insider activity scores 12.5 out of 25, with SEC Form 4 filings showing three insider transactions over the past 90 days — all of which were purchases, with zero insider sells recorded during the period. This unanimously bullish insider buying pattern suggests internal confidence in the company's forward trajectory. Dark pool activity scores a relatively low 9.3 out of 25, indicating limited notable off-exchange trading signals. Congressional trading activity registers at 12 out of 25, per 13F institutional filings, reflecting moderate legislative interest in the stock. The divergence between maximum institutional conviction and more subdued dark pool and congressional signals contributes to the composite neutral reading, though the insider purchase trend warrants monitoring for potential directional shifts.
AstraZeneca PLC delivered a significant earnings surprise in its most recently reported quarter, posting actual earnings per share of $2.63 against an analyst consensus estimate of $1.52, representing a positive surprise of $1.11, according to company earnings reports. This 73% beat underscores the strength of the company's commercial execution during the period. Looking ahead, analyst estimates project EPS of $1.44 for the quarter ending July 2026 and $1.35 for each of the two subsequent quarters, per consensus analyst estimates. The sequential decline in projected earnings from the recently reported $2.63 to $1.44 and $1.35 reflects anticipated quarterly variability rather than a structural downtrend. Investors will closely monitor the July 28, 2026 earnings release for confirmation of continued pipeline-driven revenue momentum. The upcoming November 5, 2026 report carries an identical $1.35 estimate, suggesting analysts currently model stable baseline performance across future periods.
Wall Street analyst sentiment on AstraZeneca PLC remains divided, with recent coverage reflecting a split between bullish and bearish perspectives. Berenberg Bank reiterated a Buy rating on July 13, 2026, according to Wall Street analyst reports. Jefferies has also maintained a Buy rating through consecutive reiterations on June 9 and June 26, 2026, signaling sustained confidence in the company's growth profile. Conversely, Deutsche Bank has reiterated a Sell rating twice — on June 11 and June 26, 2026 — representing a notable bearish counterpoint among major research firms, per SID consensus data. The three Buy reiterations against two Sell reiterations across the most recent five analyst actions illustrate meaningful disagreement regarding AstraZeneca's valuation at current levels. This divergence likely centers on differing views of whether the stock's 33.06 PE ratio is justified by the company's pipeline potential and commercial momentum or whether the premium valuation already captures foreseeable upside.
The latest Smart Investors Daily articles mentioning AZN.
